Published
March 8, 2025
Updated
July 27, 2026
This settlement resolves antitrust claims that Pfizer, Mylan and Teva delayed generic EpiPen to protect the brand's monopoly. It covers direct purchasers only — wholesalers, pharmacies and institutions that bought from the manufacturer for resale, not patients who filled a prescription at a pharmacy. Claims closed on May 29, 2025.
Current Status
Claims are closed. The deadline to submit a claim form was May 29, 2025. The court granted final approval of the $50 million Pfizer direct-purchaser settlement on July 9, 2024, and the $73.5 million Mylan direct-purchaser settlement reached final approval in 2025 after the court entered its preliminary approval order on February 6, 2025. No official notice that the distribution has been completed had been published as of July 27, 2026. Direct purchasers who filed should rely on the official settlement website and on communications tied to their own claim.StatusFinal Approval Granted — Distribution UnderwayNo completion date announced as of July 27, 2026.
Claim DeadlineMay 29, 2025New claims are not accepted.
Settlement Fund$123,500,000$73.5M from Mylan and $50M from Pfizer, plus Teva's contribution.
Proof RequiredYesPurchase records could be requested; claims filed on an assignment required documents proving the transfer of rights.
What Was the Case About?
Plaintiffs alleged that Pfizer, Mylan and Teva entered an unlawful market allocation agreement that delayed the launch of generic EpiPen, extending the brand's monopoly over the epinephrine auto-injector market and forcing purchasers to pay inflated prices. The defendants denied the allegations and agreed to pay a combined $123.5 million to resolve the direct-purchaser claims without admitting wrongdoing.This case is separate from the consumer and third-party-payor litigation. A separate $264 million EpiPen settlement covered ordinary consumers and insurers who paid for EpiPen at retail.
Who Was Covered?
The direct purchaser class covered people and entities in the United States, its territories and possessions, and Puerto Rico that purchased EpiPen or generic EpiPen directly from Mylan or Teva, for resale, from March 13, 2014 through February 6, 2025 — the date the court entered the preliminary approval order in the Mylan settlement.What Is a Direct Purchaser?
A direct purchaser buys the product straight from the manufacturer rather than through a retail channel. In practice this means drug wholesalers that buy in bulk from manufacturers, and institutional buyers such as hospitals, clinics and other healthcare facilities that procure drugs directly. Patients who bought an EpiPen at a pharmacy were not direct purchasers and were covered by the separate consumer litigation instead.How Much Could Claimants Get?
Individual amounts were not fixed. The combined fund is distributed among qualifying class members after court-approved fees, costs and administration expenses, with each claimant's share depending on the volume of qualifying purchases and the total number of valid claims approved. Because the class is made up largely of wholesalers and institutional buyers, allocations track purchase volume rather than a flat per-person amount.What Proof Was Required?
Claimants filing on the basis of an assignment — where another entity transferred its right to claim — had to provide documents establishing that transfer. Other claimants were not required to attach purchase records at filing, but the administrator could request proof of purchase during review, which is why this page is marked Proof Required: Yes.Why Were There Two Separate Settlements?
The alleged conduct affected different groups in different ways, so the litigation and its resolutions were structured separately. The direct purchaser settlements — $73.5 million from Mylan and $50 million from Pfizer — addressed claims by bulk buyers, while separate settlements covered consumers and insurers. A single claims website handled both direct-purchaser settlements, with separate eligibility criteria for each.What Happens Next?
With final approval entered on both settlements, the remaining steps are the resolution of any appeal and the administrator's distribution of the net funds to approved claimants. No official completion date had been announced as of July 27, 2026. Updates are posted on the official settlement website.Official information is available at EpiPen DPP Settlement.
Important Dates
• Class period: March 13, 2014 through February 6, 2025• Pfizer settlement final approval: July 9, 2024
• Mylan settlement preliminary approval: February 6, 2025
• Claim deadline: May 29, 2025
Sources
• Official settlement website: EpiPen DPP Settlement• Mylan and Pfizer settlement agreements and notice packets posted by the settlement administrator
• KPH Healthcare Services, Inc. v. Mylan N.V., No. 2:20-cv-02065-DDC-TJJ, U.S. District Court for the District of Kansas
For more class actions keep scrolling below.
Settlement Fund
$123,500,000
Case Title
KPH Healthcare Services, Inc. v. Mylan N.V. (EpiPen Direct Purchaser Action)
Case Number
2:20-cv-02065-DDC-TJJ
Court
U.S. District Court for the District of Kansas
Claim Deadline
May 29, 2025
Status
Final Approval Granted — Distribution Underway
Administrator
A.B. Data, Ltd.
Official Website
EpiPen DPP Settlement
